Sign in
Download Opera News App



SAHPRA approves Pfizer booster shots for adults and children aged from 12 years. Learn more

On Wednesday, December 8, the South African Health Products Authority (SAHPRA) approved a third dose or booster shot of the Pfizer COVID-19 vaccination for those aged 18 and up. Children with weakened immune systems, aged 12 and over, are also eligible for a second dosage.

Pfizer has applied to SAHPRA to change the dosing schedule for the Pfizer (Comirnaty) COVID-19 vaccine, allowing for an optional third dose on November 17, 2021.

According to the authority, after assessing the data given, the booster dose has been approved as follows:

In those aged 18 and over, a third dose of the Comirnaty COVID-19 vaccine should be given at least 6 months following the second dose.

A third dose of the Comirnaty COVID-19 vaccine should be given at least 28 days after the second jab to anyone aged 12 and up who are severely immunocompromised.

SAHPRA stated that the data it examined only considered scenarios in which the third dose of the vaccine is the same as the first. As a result, anyone who have already received a Johnson and Johnson vaccine will not be able to get another one.

"SAHPRA recognizes the intense interest in the efficacy and safety of heterologous boosting regimens (so-called'mix and match' techniques) and invites submission of supportive evidence in this area," stated SAHPRA CEO Dr Boitumelo Semete.

What are your thoughts on this topic in light of this? Please feel free to express your thoughts in the comments box below, and remember to follow my account for updates and other information. Please forward this article to your friends and family so they don't miss out on this important information. This is critical information for them to have.

Just before you go, let us see what the world is saying about this approved Pfizer booster online. We really need to work together on this if we want to be out of lockdown soon.


Content created and supplied by: Owl24/7 (via Opera News )

Comirnaty Pfizer SAHPRA South African Health Products Authority


Load app to read more comments